Gyre Therapeutics (NASDAQ:GYRE) Stock Price Up 14.3% - Should You Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares rose 14.3% during trading on Monday . The company traded as high as $10.86 and last traded at $10.89. Approximately 64,824 shares were traded during trading, a decline of 32% from the average daily volume of 94,744 shares. The stock had previously closed at $9.53.

Analyst Upgrades and Downgrades

Separately, Noble Financial started coverage on shares of Gyre Therapeutics in a report on Tuesday, March 11th. They issued an "outperform" rating for the company.

Gyre Therapeutics Price Performance

The firm has a market capitalization of $1.06 billion, a P/E ratio of 567.50 and a beta of 1.90. The firm's fifty day moving average price is $9.08 and its 200-day moving average price is $10.85.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its earnings results on Friday, May 9th. The company reported $0.03 earnings per share for the quarter, hitting analysts' consensus estimates of $0.03. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%. The firm had revenue of $22.06 million during the quarter, compared to the consensus estimate of $28.40 million.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Gyre Therapeutics by 15,083.3% in the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after acquiring an additional 1,810 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Gyre Therapeutics by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after purchasing an additional 913 shares during the last quarter. Bank of America Corp DE boosted its holdings in Gyre Therapeutics by 40.4% during the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company's stock worth $84,000 after buying an additional 1,996 shares in the last quarter. Barclays PLC grew its position in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after buying an additional 6,855 shares during the last quarter. Finally, Advantage Alpha Capital Partners LP increased its holdings in shares of Gyre Therapeutics by 54.0% in the first quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock valued at $105,000 after buying an additional 4,790 shares in the last quarter. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.